Clinical Trial 16480

Cancer Type: Multiple
Study Type: Other
NCT#: NCT01302626

Phase: N/A
Principal Investigator: Gillies, Robert

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

Radiomics: A Prospective Study of Outcome in Lung Cancer

Summary

The main purpose of this study is to gather information related to lung cancer to improve the predictive model for survival and long term toxicity.

Objective

1. The main aim is to collect data of patients with all stages of lung cancer, and to perform different analyses on this data, for the purpose of improving and validating the predictive model for survival and long term toxicity in lung cancer. 2. Long term aim is to build a Decision Support System based on the predictive models validated in this study.

Treatments

Therapies

Medications

Inclusion Criteria

>>>

Age 18 years or older

Histological or cytological proven lung cancer (with priority on SCLC and NSCLC stage II/III to increase the currently limited tumor tissue bank of these tumor subgroups)

Informed consent according to national rules (US: written informed consent, NL: no objection rule)

Exclusion Criteria

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trials Search

Advanced Search